Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

被引：0
|
作者：
Hong, David S.
Strickler, John H.
Fakih, Marwan
Falchook, Gerald Steven
Li, Bob T.
Durm, Greg Andrew
Burns, Timothy F.
Ramalingam, Suresh S.
Goldberg, Sarah B.
Frank, Richard C.
Marrone, Kristen
Shu, Catherine A.
Gandara, David R.
Soman, Neelesh
Henary, Haby Adel
Govindan, Ramaswamy
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] City Hope Comprehens Med Ctr, Duarte, CA USA
[4] Sarah Cannon Res Inst, Denver, CO USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Yale Sch Med, New Haven, CT USA
[10] Nuvance Hlth, Norwalk, CT USA
[11] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Columbia Univ, Med Ctr, New York, NY USA
[13] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[14] Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA
[15] Amgen Inc, Thousand Oaks, CA 91320 USA
[16] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS2669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2669
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Pachter, Jonathan A.
    Koustenis, Andrew G.
    Patrick, Gloria
    Denis, Louis J.
    CANCER RESEARCH, 2022, 82 (12)
  • [32] A Phase 1b Study of the MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination with Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer
    Steuer, C.
    Carlisle, J.
    Leal, T.
    Ardeshir, F.
    Holmes, M.
    Schneider, F.
    Chen, Z.
    Switchenko, J.
    Ross, J.
    Selvagi, G.
    Owonikoko, T.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S196 - S196
  • [33] A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
    Koh, R. Keng
    Califano, R.
    Dean, E.
    Kosmin, J.
    Ataman, O.
    Jackson, A.
    Blackhall, F. H.
    Faivre-Finn, C.
    LUNG CANCER, 2010, 67 : S33 - S34
  • [34] A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
    Rajiv Kumar
    Shir Kiong Lu
    Anna Minchom
    Adam Sharp
    Michael Davidson
    Ranga Gunapala
    Timothy A. Yap
    Jaishree Bhosle
    Sanjay Popat
    Mary E. R. O’Brien
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 375 - 383
  • [35] A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
    Plummer, Ruth
    Dean, Emma
    Arkenau, Hendrik-Tobias
    Redfern, Charles
    Spira, Alexander I. I.
    Melear, Jason M. M.
    Chung, Ki Y. Y.
    Ferrer-Playan, Jordi
    Goddemeier, Thomas
    Locatelli, Giuseppe
    Dong, Jennifer
    Fleuranceau-Morel, Patricia
    Diaz-Padilla, Ivan
    Shapiro, Geoffrey I. I.
    LUNG CANCER, 2022, 163 : 19 - 26
  • [36] A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
    Kumar, Rajiv
    Lu, Shir Kiong
    Minchom, Anna
    Sharp, Adam
    Davidson, Michael
    Gunapala, Ranga
    Yap, Timothy A.
    Bhosle, Jaishree
    Popat, Sanjay
    O'Brien, Mary E. R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (02) : 375 - 383
  • [37] PHASE I TRIAL OF IRREVERSIBLE PAN-ERBB INHIBITOR DACOMITINIB (DAC) IN COMBINATION WITH ALK/MET INHIBITOR CRIZOTINIB (CRIZ) IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Janne, P. A.
    Shaw, A. T.
    Giaccone, G.
    Camidge, D. R.
    Shreeve, S. M.
    Goldberg, Z.
    Tang, Y.
    Solomon, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 423 - 423
  • [38] A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
    Cho, Byoung Chul
    Goldberg, Sarah B.
    Kim, Dong-Wan
    Socinski, Mark A.
    Burns, Timothy F.
    Lwin, Zarnie
    Pathan, Nuzhat
    Ma, Wei Dong
    Masters, Joanna C.
    Cossons, Nandini
    Wilner, Keith
    Nishio, Makoto
    Husain, Hatim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (07) : 747 - 757
  • [39] Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)
    von Itzstein, Mitchell S.
    Burns, Timothy F.
    Dowell, Jonathan
    Horn, Leora
    Camidge, David Ross
    York, Sally J.
    Eaton, Keith D.
    Walker, Christopher James
    Zhang, Song
    Gerber, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Awad, Mark M.
    Gadgeel, Shirish M.
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345